Amgen Sees Strong Q4 Growth Even Without Horizon Contribution

Gains Driven By Volume For Many Products

 
• By Mandy Jackson
  
Generate a summary of this article
Listen to this article
Beta

The company increased its full-year guidance in anticipation of Horizon’s Q4 contribution and sales for the quarter jumped 20%, but even excluding those drugs product sales were up 5%.

Amgen logo sign hanging on the office building in Rotkreuz, Switzerland
Amgen's full-year 2024 revenue guidance is $32.4bn-$33.8bn • Source: Shutterstock

Amgen, Inc.’s revenue surged during the fourth quarter of 2023, powered largely by the rare disease drug portfolio from its $27.8bn Horizon Therapeutics plc acquisition that closed during the quarter, but the company also saw significant growth for several products outside of those assets, including the osteoporosis drugs Prolia (denosumab) and Evenity (romosozumab) and LDL-lowering therapy Repatha (evolocumab).

Key Takeaways

  • Amgen’s Q4 revenue and product sales each rose 20%, based in large part on the contribution of Horizon’s rare disease drugs, but sales jumped 5% even without these newly purchased assets.

Amgen raised its full year 2023 revenue guidance by about $1bn to a range of $28bn-$28.4bn in November in anticipation...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Business

Test Roche Head Of Pharma Strategy Karsten Jung On Rebuilding The Portfolio

 
• By Jessica Merrill

The Swiss pharma company is rebalancing the portfolio, emphasizing best-in-class drugs and moving into new areas like cardiovascular and metabolic disease.

Quick Listen: Scrip’s Five Must-Know Things

 
• By Reed Miller

In this week's episode: Trump’s UK drug pricing win; Novo explains semaglutide Alzheimer's rationale; J&J and Novartis on this year’s biggest M&A deals; a look at the mixed performance of CAR-Ts; and Akeso’s goals beyond ivonescimab.

Article Without An Author Listed

Here is a short description.

Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]

Pipelines in bioconjugates continue to develop, from ADCs to XDCs, with radionuclide drug conjugates (RDCs) and antibody-oligonucleotide conjugates (AOCs) leading the expansion.

More from Scrip

EHA: Lilly’s Jaypirca Posts First Phase III Triplet Win In CLL While BTK Degraders Advance

Lilly's first Phase III triplet win opens the door to a label expansion in BTK-pretreated CLL, with analysts suggesting Jaypica could attain blockbuster status. However, the window to capitalize may be brief as next-generation BTK degraders close in with head-to-head trials.

EHA: Lilly’s Jaypirca Posts First Phase III Triplet Win In CLL While BTK Degraders Advance - Clone

Lilly's first Phase III triplet win opens the door to a label expansion in BTK-pretreated CLL, with analysts suggesting Jaypica could attain blockbuster status. However, the window to capitalize may be brief as next-generation BTK degraders close in with head-to-head trials.